Paricalcitol
Other Anti-Parathyroid Agents
- Drug class
- Other Anti-Parathyroid Agents
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 4
- FDA reports (12 mo)
- 32
Overview
Plain-language summary, compiled from the cited regulatory records
Paricalcitol is a medication classified as an Other Anti-Parathyroid Agent [1]. It is approved for adults for the prevention and treatment of secondary hyperparathyroidism in individuals with Chronic Kidney Disease (CKD) Stages 3 and 4 [1]. While pediatric use information for patients aged 10 to 16 years is available for a branded version of paricalcitol, this specific product is not labeled with that information due to marketing exclusivity [1].
In the past 12 months, there have been 32 adverse event reports associated with paricalcitol [2]. The most frequently reported adverse events include drug ineffectiveness, osteomalacia, vitamin D deficiency, calciphylaxis, and parathyroid tumor benign [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 3 | March 13, 2026 |
| US United States | FDA | 1 | May 26, 2017 |
GBUnited Kingdom· MHRA
3 products
Uses
Zemplar is indicated in adult and paediatric patients 10 to 16 years of age for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stages 3 and 4. Zemplar is indicated in adult patients for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5 in patients who are on haemodialysis or peritoneal dialysis.
How to take
USUnited States· FDA
1 product
Uses
1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. ’s Zemplar (Paricalcitol) capsules.
’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD).
’s Zemplar (Paricalcitol) capsules. ’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1). 2).
How to take
Drug interactions
Known interactions involving Paricalcitol. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL410420011 · revised March 13, 2026
- [2]FDA DailyMed · 0fbaff52-f08f-42… · revised May 26, 2017 [PDF]
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.